Shuhong Wang
Kaifeng, 475004, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications
Chemotactic sensing of extracellular antibiotic resistance genes enables their efficient removal by Stutzerimonas stutzeri.
Journal: Journal of hazardous materials
Published: June 18, 2026
Caspase-1-mediated pyroptosis drives secondary thalamic neurodegeneration after focal cerebral infarction.
Journal: Molecular biology reports
Published: April 05, 2026
Integrative multi-kingdom gut microbiome analysis uncovers clinical signatures of major depressive disorder.
Journal: Journal of affective disorders
Published: March 11, 2026
Continuous Alterations in the Gut Microbial Landscape Associated With Suicidal Ideation in First-Episode Drug-naïve Major Depressive Disorder.
Journal: CNS neuroscience & therapeutics
Published: December 02, 2025
Dissecting the Ecological Structure of Health and Disease in the Global Gut Microbiome.
Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Published: September 02, 2025
Age-related decline in hippocampal tyrosine phosphatase PTPRO is a mechanistic factor in chemotherapy-related cognitive impairment.
Journal: JCI insight
Published: October 17, 2022
Neoantigen-based cancer vaccination using chimeric RNA-loaded dendritic cell-derived extracellular vesicles.
Journal: Journal of extracellular vesicles
Published: August 24, 2021
Correction: Repurposing dextromethorphan and metformin for treating nicotine-induced cancer by directly targeting CHRNA7 to inhibit JAK2/STAT3/SOX2 signaling.
Journal: Oncogene
Published: July 24, 2021
Harnessing the soil: reshaping the tumor microenvironment towards an antitumor immune state by low-dose metformin.
Journal: Cancer communications (London, England)
Published: April 15, 2021
Repurposing dextromethorphan and metformin for treating nicotine-induced cancer by directly targeting CHRNA7 to inhibit JAK2/STAT3/SOX2 signaling.
Journal: Oncogene
Published: September 11, 2020
Low-Dose Metformin Reprograms the Tumor Immune Microenvironment in Human Esophageal Cancer: Results of a Phase II Clinical Trial.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: January 14, 2020
Metformin induces human esophageal carcinoma cell pyroptosis by targeting the miR-497/PELP1 axis.
Journal: Cancer letters
Published: December 04, 2018
Last Updated: 09/26/2026